Fed. Circ. Keeps Teva Out Of Luck Over Crestor Patent

Law360, New York (December 1, 2011, 4:42 PM EST) -- Teva Pharmaceutical Industries Ltd. lost its bid Thursday to overturn a lower court's ruling that AstraZeneca PLC did not infringe a Teva patent through its sales of the billion-dollar cholesterol drug Crestor.

The Court of Appeals for the Federal Circuit upheld the ruling by the U.S. District Court for the Eastern District of Pennsylvania, which held that Teva’s patent for a stabilized statin formulation of rosuvastatin calcium for the treatment of dyslipidemia was invalid since AstraZeneca first produced a batch of the drug, the opinion said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.